Id: acc0162
Group: 1sens
Protein: merlin
Gene Symbol: NF2
Protein Id: P35240
Protein Name: MERL_HUMAN
PTM: phosphorylation
Site: Ser315
Site Sequence: LFMRRRKADSLEVQQMKAQAR
Disease Category: Cancer
Disease: Schwannoma
Disease Subtype: schwannoma
Disease Cellline: RT4-D6P2T
Disease Info:
Drug: phosphatidylinositols
Drug Info: -
Effect: inhibit
Effect Info: Akt phosphorylation enhances the binding affinity of merlin to phosphatidylinositol and inhibits its pro - apoptotic effect.
Note:
Score: 5.0
Pubmed(PMID): 19351837
Sentence Index:
Sentence:

Sequence & Structure:

MAGAIASRMSFSSLKRKQPKTFTVRIVTMDAEMEFNCEMKWKGKDLFDLVCRTLGLRETWFFGLQYTIKDTVAWLKMDKKVLDHDVSKEEPVTFHFLAKFYPENAEEELVQEITQHLFFLQVKKQILDEKIYCPPEASVLLASYAVQAKYGDYDPSVHKRGFLAQEELLPKRVINLYQMTPEMWEERITAWYAEHRGRARDEAEMEYLKIAQDLEMYGVNYFAIRNKKGTELLLGVDALGLHIYDPENRLTPKISFPWNEIRNISYSDKEFTIKPLDKKIDVFKFNSSKLRVNKLILQLCIGNHDLFMRRRKADSLEVQQMKAQAREEKARKQMERQRLAREKQMREEAERTRDELERRLLQMKEEATMANEALMRSEETADLLAEKAQITEEEAKLLAQKAAEAEQEMQRIKATAIRTEEEKRLMEQKVLEAEVLALKMAEESERRAKEADQLKQDLQEAREAERRAKQKLLEIATKPTYPPMNPIPAPLPPDIPSFNLIGDSLSFDFKDTDMKRLSMEIEKEKVEYMEKSKHLQEQLNELKTEIEALKLKERETALDILHNENSDRGGSSKHNTIKKLTLQSAKSRVAFFEEL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
NF2-Ser315
Cancer Intensity
BRCA 0.862
COAD 1.289
HGSC
ccRCC -0.15
GBM -0.687
HNSC -1.722
LUAD -0.281
LUSC 1.556
non_ccRCC 0.163
PDAC -0.32
UCEC -0.71

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - A Colon cancer/carcinoma Phosphorylation 24323642
- - D Triple-negative breast cancer Phosphorylation 37368176
S 518 U Mesothelioma Phosphorylation 18835652

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P35240 NF2 P Ser315 KADS(ph)LEVQQMK A549 Tideglusib 7.5505 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: